Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03313687

SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK

International, observational registry to investigate the outcome in patients with cardiogenic shock. The primary aim of this study is to investigate the clinical outcome of patients in cardiogenic shock.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cardiogenic Shock Cardiovascular Diseases Heart Diseases Infarction Ischemia Myocardial Infarction Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms Shock Shock, Cardiogenic Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Heart Center

Hamburg, Germany

Location status: Recruiting

Location contact

Benedikt Schrage, MD

CONTACT

Dirk Westermann, MD

CONTACT

About this study

There is a focus on interventional therapies, mechanical circulatory support and new cardiovascular therapeutics in patients with cardiogenic shock (CS). The investigators will describe current practice in study sites including concomitant patients with CS. Therefore, the investigators will monitor drug therapies initiated, devices being utilized as well as outcome and side effect of possible interventions

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with cardiogenic shock treated at a tertiary care hospital.

Exclusion criteria

  • Age ≤17 years.

Treatment and study plan

Primary outcomes

  1. All-cause mortality

    Time frame: Within 30 days after admission.

    by registration office

Secondary outcomes

  1. Ischemic events, bleeding events, heart failure, sepsis, dialysis.

    Time frame: Within 30 days after admission.

    by survey, number of ischemic events, number of bleeding events, number of patients developing heart failure as well as heart failure severity (NYHA), patients developing terminal kidney failure requiring dialysis.

  2. All-cause mortality

    Time frame: Within 12 months after admission.

    by registration office

  3. Ischemic events, bleeding events, heart failure, sepsis, dialysis.

    Time frame: Within 12 months after admission.

    by survey, number of ischemic events, number of bleeding events, number of patients developing heart failure as well as heart failure severity (NYHA), patients developing terminal kidney failure requiring dialysis.

Study contacts

Contact information is provided by the study sponsor or research team.

Benedikt Schrage, MD

CONTACT

[email protected]

+49 40 7410 18135

Dirk Westermann, MD

CONTACT

[email protected]

+49 40 7410 54864

Sponsors and collaborators

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf

Other

Registry information

Official study title

SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK - an International, Observational Registry

Acronym: STOP-SHOCK

Important dates

Study start
2017
Primary completion
2030
Study completion
2031
First posted
Oct 18, 2017
Registry last updated
Oct 7, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.